Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 1
Submit an article Journal homepage
4,142
Views
3
CrossRef citations to date
0
Altmetric
Coronavirus – Letters

COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies

Nir Eyala Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ, USA;b Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1056-6609View further author information
ORCID Icon,
Arthur Caplanc Division of Medical Ethics, Grossman School of Medicine, New York University Langone, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-4061-8011View further author information
ORCID Icon &
Stanley Plotkind Emeritus Professor Department of Pediatrics, University of Pennsylvania. Vaxconsult, Doylestown, PA, USAView further author information
Article: 1917240 | Received 30 Mar 2021, Accepted 08 Apr 2021, Published online: 27 Apr 2021

References

  • Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021. doi:10.1038/s41586-021-03398-2.
  • Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE, De Oliveira T, Vermeulen M, Van Der Berg K, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021. doi:10.1038/s41591-021-01285-x.
  • Moderna. Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa; 2021. [accessed 2021 April 14]. https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against.
  • Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, Sarkar R, Chen W, Cutler M, et al. Neutralizing activity of BNT162b2-elicited serum - preliminary report. N Engl J Med. 2021. doi:10.1056/NEJMc2102017.
  • Boseley S. WHO backs use of Oxford/AstraZeneca Covid vaccine for adults of all ages. Guardian. 2021.
  • FDA. Fact sheet for healthcare providers administering vaccine—Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent Coronavirus disease 2019 (COVID-19); 2021. [accessed 2021 April 14]. https://www.fda.gov/media/146304/download
  • Bonifield J. Moderna designs updated Covid-19 vaccine to combat South Africa coronavirus variant. CNN. 2021.
  • Wendler D, Ochoa J, Millum J, Grady C, Taylor HA. Vaccine trial ethics once we have efficacious vaccines. Science. 2020;370(6522):1277–2. doi:10.1126/science.abf5084.
  • Iyer AA, Millum J, Grady C, Wendler D. Avoiding exploitation in multinational covid-19 vaccine trials. Bmj. 2021;372:n541. doi:10.1136/bmj.n541.
  • Eyal N, Lipsitch M. How to test SARS-CoV-2 vaccines ethically even after one is available. Clin Infect Dis. 2021. doi:10.1093/cid/ciab182.
  • Manheim D, Wiecek W, Schmidt V, Morrison J; 1Day Sooner Research Team. Exploring risks of human challenge trials for COVID-19. Risk Anal. Forthcoming 2021.
  • Park A. It’s not clear that we actually need human challenge trials for COVID-19, but the U.K. is moving ahead with them anyway. Time. 2021.
  • Schwedes L. Britain first to infect healthy volunteers with coronavirus for study. DPA Int. 2021, March 7.
  • Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. Bmj. 2021;372:n579. doi:10.1136/bmj.n579.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.